Literature DB >> 21122914

Real-time monitoring of sustained drug release using the optical properties of porous silicon photonic crystal particles.

Elizabeth C Wu1, Jennifer S Andrew, Lingyun Cheng, William R Freeman, Lindsey Pearson, Michael J Sailor.   

Abstract

A controlled and observable drug delivery system that enables long-term local drug administration is reported. Biodegradable and biocompatible drug-loaded porous Si microparticles were prepared from silicon wafers, resulting in a porous 1-dimensional photonic crystal (rugate filter) approx. 12 μm thick and 35 μm across. An organic linker, 1-undecylenic acid, was attached to the Si-H terminated inner surface of the particles by hydrosilylation and the anthracycline drug daunorubicin was bound to the carboxy terminus of the linker. Degradation of the porous Si matrix in vitro was found to release the drug in a linear and sustained fashion for 30 d. The bioactivity of the released daunorubicin was verified on retinal pigment epithelial (RPE) cells. The degradation/drug delivery process was monitored in situ by digital imaging or spectroscopic measurement of the photonic resonance reflected from the nanostructured particles, and a simple linear correlation between observed wavelength and drug release was observed. Changes in the optical reflectance spectrum were sufficiently large to be visible as a distinctive red to green color change.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21122914      PMCID: PMC3025697          DOI: 10.1016/j.biomaterials.2010.11.013

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  33 in total

1.  Intravitreal injections: does globe size matter?

Authors:  Klaus D Teichmann
Journal:  J Cataract Refract Surg       Date:  2002-10       Impact factor: 3.351

2.  Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle.

Authors:  L Cheng; E Anglin; F Cunin; D Kim; M J Sailor; I Falkenstein; A Tammewar; W R Freeman
Journal:  Br J Ophthalmol       Date:  2008-05       Impact factor: 4.638

3.  Inhibition of anthracycline semiquinone formation by ICRF-187 (dexrazoxane) in cells.

Authors:  K L Malisza; B B Hasinoff
Journal:  Free Radic Biol Med       Date:  1996       Impact factor: 7.376

4.  Microfabricated porous silicon particles enhance paracellular delivery of insulin across intestinal Caco-2 cell monolayers.

Authors:  Amy B Foraker; Rob J Walczak; Michael H Cohen; Tony A Boiarski; Carl F Grove; Peter W Swaan
Journal:  Pharm Res       Date:  2003-01       Impact factor: 4.200

5.  Biodegradable luminescent porous silicon nanoparticles for in vivo applications.

Authors:  Ji-Ho Park; Luo Gu; Geoffrey von Maltzahn; Erkki Ruoslahti; Sangeeta N Bhatia; Michael J Sailor
Journal:  Nat Mater       Date:  2009-02-22       Impact factor: 43.841

Review 6.  Proliferative vitreoretinopathy and chemotherapeutic agents.

Authors:  G A Peyman; J Schulman
Journal:  Surv Ophthalmol       Date:  1985 May-Jun       Impact factor: 6.048

7.  Failure of MTT as a toxicity testing agent for mesoporous silicon microparticles.

Authors:  Timo Laaksonen; Hélder Santos; Henna Vihola; Jarno Salonen; Joakim Riikonen; Teemu Heikkilä; Leena Peltonen; Narendra Kumar; Dmitry Yu Murzin; Vesa-Pekka Lehto; Jouni Hirvonen
Journal:  Chem Res Toxicol       Date:  2007-11-09       Impact factor: 3.739

8.  Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy.

Authors:  J A Khawly; P Saloupis; D L Hatchell; R Machemer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

9.  Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages.

Authors:  Y N Hui; H C Liang; Y S Cai; B Kirchhof; K Heimann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-02       Impact factor: 3.117

10.  Daunomycin in the treatment of experimental proliferative vitreoretinopathy. Effective doses in vitro and in vivo.

Authors:  P Wiedemann; N Sorgente; C Bekhor; R Patterson; T Tran; S J Ryan
Journal:  Invest Ophthalmol Vis Sci       Date:  1985-05       Impact factor: 4.799

View more
  21 in total

1.  Cisplatin-loaded porous Si microparticles capped by electroless deposition of platinum.

Authors:  Jennifer S Park; Joseph M Kinsella; Danielle D Jandial; Stephen B Howell; Michael J Sailor
Journal:  Small       Date:  2011-06-01       Impact factor: 13.281

2.  Sustained delivery of a HIF-1 antagonist for ocular neovascularization.

Authors:  Takeshi Iwase; Jie Fu; Tsunehiko Yoshida; Daisuke Muramatsu; Akiko Miki; Noriyasu Hashida; Lili Lu; Brian Oveson; Raquel Lima e Silva; Christopher Seidel; Ming Yang; Sheila Connelly; Jikui Shen; Bing Han; Mingsheng Wu; Gregg L Semenza; Justin Hanes; Peter A Campochiaro
Journal:  J Control Release       Date:  2013-10-12       Impact factor: 9.776

3.  Porous silicon oxide-PLGA composite microspheres for sustained ocular delivery of daunorubicin.

Authors:  Kaihui Nan; Feiyan Ma; Huiyuan Hou; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  Acta Biomater       Date:  2014-05-02       Impact factor: 8.947

4.  A Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics.

Authors:  Huiyuan Hou; Kristyn Huffman; Sandy Rios; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-04       Impact factor: 4.799

5.  Self-Reporting Photoluminescent Porous Silicon Microparticles for Drug Delivery.

Authors:  Joanna Wang; Tushar Kumeria; Maria Teresa Bezem; Jian Wang; Michael J Sailor
Journal:  ACS Appl Mater Interfaces       Date:  2018-01-16       Impact factor: 9.229

6.  Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system.

Authors:  Jay Chhablani; Alejandra Nieto; Huiyuan Hou; Elizabeth C Wu; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-01       Impact factor: 4.799

Review 7.  Nanotechnologies for noninvasive measurement of drug release.

Authors:  Thomas Moore; Hongyu Chen; Rachel Morrison; Fenglin Wang; Jeffrey N Anker; Frank Alexis
Journal:  Mol Pharm       Date:  2013-11-26       Impact factor: 4.939

8.  Hydrosilylated porous silicon particles function as an intravitreal drug delivery system for daunorubicin.

Authors:  Kathrin I Hartmann; Alejandra Nieto; Elizabeth C Wu; William R Freeman; Jae Suk Kim; Jay Chhablani; Michael J Sailor; Lingyun Cheng
Journal:  J Ocul Pharmacol Ther       Date:  2013-02-28       Impact factor: 2.671

9.  Ocular silicon distribution and clearance following intravitreal injection of porous silicon microparticles.

Authors:  Alejandra Nieto; Huiyuan Hou; Michael J Sailor; William R Freeman; Lingyun Cheng
Journal:  Exp Eye Res       Date:  2013-09-10       Impact factor: 3.467

10.  Protection and Delivery of Anthelmintic Protein Cry5B to Nematodes Using Mesoporous Silicon Particles.

Authors:  Chia-Chen Wu; Yan Hu; Melanie Miller; Raffi V Aroian; Michael J Sailor
Journal:  ACS Nano       Date:  2015-05-20       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.